Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Rang in Aktien #4543
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aktienkurs
$27.18
Zuletzt synchronisiert: 2026-07-31
Marktkapitalisierung
$3.38B
Veränderung (1 Tag)
-1.41%
Veränderung (1 Jahr)
202.34%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)

Kategorie

Healthcare
Aktien-Split-Historie für Tango Therapeutics, Inc. (TNGX)
Die Aktie Tango Therapeutics, Inc. (Symbol: TNGX) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Oct 21, 2026 statt.
Eine TNGX-Aktie, die vor dem Oct 21, 2026 gekauft wurde, entspricht heute 0 TNGX-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL